Sotalol is unique among beta-adrenergic blocking drugs in possessing significant class III antiarrhythmic actions. The present study was designed to assess the relative concentration dependence of beta-blocking and class III actions of sotalol and to relate the findings to concentrations achieved during oral sotalol therapy in humans. Measurements were made in anesthetized dogs under control conditions, and then in the presence of a series of stable sotalol plasma concentrations produced by sequential loading and maintenance infusions.
Sotalol is unique among beta-adrenergic blocking drugs in possessing significant class III antiarrhythmic actions. The present study was designed to assess the relative concentration dependence of beta-blocking and class III actions of sotalol and to relate the findings to concentrations achieved during oral sotalol therapy in humans. Measurements were made in anesthetized dogs under control conditions, and then in the presence of a series of stable sotalol plasma concentrations produced by sequential loading and maintenance infusions.
Beta-blocking effects of sotalol, determined by attenuation of the chronotropic actions of isoproterenol, were seen at the lowest dose used. Increases in atria1 and ventricular refractory periods (observed in dogs with autonomic blockSotalol is a beta-adrenergic blocking agent that also directly increases action potential duration (1,2). This action makes it unique among beta-blocking drugs and results in potentially important antiarrhythmic properties (3) . In fact, sotalol was the first class III antiarrhythmic agent to be so classified (1). Initial in vitro studies indicated that the beta-blocking dose of sotalol is much less than the dose required to alter repolarization (2). Wang et al. (4) showed that the sotalol dose that produced 50% of maximal beta-blockade (320 mgl day) was much lower than the dose (960 mg/day) at which significant prolongation of the corrected QT interval (QT,) occurred in all patients. This observation suggests that doses much higher than the beta-blocking doses of sotalol are ade to exclude beta-receptor-mediated or reflex autonomic effects) required much larger doses of sotalol. Half-maximal beta-blocking effects occurred at an average sotaiol concentration of 0.8 f 0.3 mg/liter, an order of magnitude lower than the concentrations required for half-maximal effects on atrial (6.9 + 1.2 mg/liter, p < 0.01) and ventricular (6.8 f 2.8 mg/liter, p < 0.05) refractoriness.
These results show that substantially higher concentrations are needed for the class III effects of sotalol than for its beta-blocking action. These pharmacodynamic differences need to be considered in evaluating the antiarrhythmic efficacy and mechanisms of this unusual drug.
(J Am Co11 Cardioll989:13:1190-4) necessary for type III electrophysiologic actions in humans.
The present experiments were designed to compare the concentration-response relations for the beta-blocking and for the pure class III effects of sotalol in dogs.
Methods
Experimental preparation. A total of 12 mongrel dogs were anesthetized with morphine (2 mg/kg subcutaneously) and alpha-chloralose (100 mglkg intravenously). They were ventilated mechanically by means of an endotracheal tube at a rate of 15 respirations/min and with a tidal volume obtained from a nomogram. Arterial blood gases were measured, and ventilation adjusted to maintain a partial pressure of oxygen (PoJ X30 torr and a pH of 7.38 to 7.45. Catheters were inserted into a femoral artery and both femoral veins. Two electrocardiographic (ECG) leads and arterial blood pressure we_-: monitored continuously with the use of a Grass polygraph recorder.
Sotalol dosage. The effects of five dose levels of sotalol were determined in the 12 dogs. Loading and maintenance doses of sotalol were calculated to produce a series of steady state plasma concentrations (Table 1 ). All loading doses Table 1 for definition of doses 1 tos.
standard and there was complete baseline separation. The amplitude of each signal was compared with a calibration curve from a three-point (duplicate sample) standard curve performed on the same day. The mean coefficient of variation was 3.3% and the lower limit of detection was 0.125 mgl liter.
Solutions and chemicals. Isoproterenol hydrochloride was obtained from Sigma Chemical Inc. and administered in a mixture of isotonic saline solution and 0.1% ascorbic acid to prevent oxidation. Both d,l-sotalol and MJ 8181 (internal standard) were supplied by Bristol Myers Corp. Sotalol was administered in isotonic saline solution.
Statistical methods. Group values are presented as the mean values ? SE. Comparisons between groups of data were performed by analysis of variance with a range test, and comparisons between two means only were performed by Student's t test for either paired or unpaired samples (6).
A two-tailed p value co.05 was taken to indicate statistical significance.
Results
Effects of sotalol. Sotalol produced a dose-related, parallel shift of the isoproterenol dose-response curve in the six autonomically intact dogs, as expected for a competitive beta-blocker (Fig. 1) . As a result of its type III actions, sotalol caused a dose-related increase in atria1 and ventricular effective refractory period ( Table 2 ). Significant changes in refractoriness occurred at doses higher than those required for a statistically significant rightward shift in the isoproterenol dose-response curve (as indicated by the ED,,).
Concentration dependence of beta-blocking and type III actions. Plasma concentrations of sotalol were slightly higher in the six dogs with autonomic blockade (Table l) , but the differences in plasma concentrations were not statistically significant at any dose level. Concentration-response analysis revealed major differences in the concentration dependence of the beta-blocking and type III actions of sotalol (Fig. 2) . Half-maximal beta-blocking effects were seen at a mean concentration of 0.8 ? 0.3 mg/liter. This value was substantially lower than the concentrations required for half-maximal effects on atria1 effective refractory period (6.9 2 1.2 mglliter, p < 0.01) or ventricular effective refractory period (6.8 + 2.8 mg/liter, p < 0.05). Sotalol produced larger changes in atria1 than in ventricular effective refractory period, and the difference between the magnitude of these effects was significant (p < 0.05) for the largest dose of sotalol. Sotalol's effect on neither atria1 effective refractory period nor ventricular effective refractory period was frequency dependent.
Discussion
Sotalol is a beta-adrenergic receptor antagonist with unique class III antiarrhythmic action (3) . Its clinical use is increasing because of its unique profile of action and the limited availability of class III compounds. Because it has *Isoproterenol ED,, = dose of isoproterenol required for 50% of maximal heart rate change, obtained from the isoproterenol dose-response curve; atrial, ventricular ERP = atria1 and ventricular effective refractory period, respectively, determined by the extrastimulus technique. tp < 0.05; Sp < 0.01 compared with corresponding control value. Isoproterenol EDSo was measured before and after various doses of sotalol in six autonomically intact dogs. Pure type III effects of sotalol as reflected by changes in atrial and ventricular effective refractory period (ERP) were evaluated in a separate set of six dogs with autonomic blockade as described in the text. The doses of sotalol used and the resulting plasma concentrations are shown in Table I . two clinically relevant actions, beta-blocking and direct membrane (class III) effects, it is important to know the concentration ranges over which each action is expected to play a role. Pure beta-blockers such as metoprolol have been found to produce statistically significant (albeit modest) increases in QT interval and monophasic action potential duration (7). It is therefore necessary to eliminate the effect of beta-receptor-mediated changes in repolarization to analyze the concentration dependence of pure type III actions of sotalol. We achieved this state in our dogs by first producing chemical autonomic blockade and then comparing refractory periods before and after sotalol in the continuous absence of beta-mediated sympathetic effects.
Comparison with other studies of sotalol's actions. We found a major disparity between the sotalol concentrations producing substantial beta-blockade and those required to increase atria1 and ventricular refractory periods in dogs by class III actions. This disparity is consistent with in vitro data (2, 8) suggesting that sotalol blocks the effects of betaagonists at concentrations much lower than those increasing action potential duration. Clinical studies (4, 9) have also indicated that significant QT, prolongation by sotalol requires concentrations substantially higher than those preventing exercise-induced tachycardia.
We found that half-maximal beta-blockade occurred at a sotalol concentration of 0.8 + 0.3 mglliter. This finding is similar to the results of Wang et al. (4) , who observed 50% of maximal attenuation of exercise-induced tachycardia in patients at a concentration of 0.8 mgiliter. On the other hand, we observed half-maximal increases in atria1 and ventricular refractory period at sotalol plasma concentrations of 6.9 and 6.8 mg/liter, respectively. Maximal increases in atria1 and ventricular effective refractory period averaged 32.2 ? 4.0% and 20.8 t 3.3%, respectively, at a cumulative sotalol loading dose of 8.84 mg/kg. These values are in the range of values reported by other investigators, who found that 4.5 mgikg of sotalol increased ventricular effective refractory period in normal tissues by 14% (10) and 8 mgikg increased ventricular effective refractory period by 15 to 20% (11) in conscious dogs. These results are also in keeping with the degree of action potential duration prolongation in ventricular muscle produced by a similar range of concentrations in vitro (1. 2, 8, 12) .
Our study differs from previous in vivo pharmacodynamic e\laluations of sotalol's beta-blocking and type III actions (4, 9) in several important ways. We evaluated pure class III actions of sotalol by eliminating autonomic influences through chemical autonomic blockade. Our analysis of betablocking action was based on isoproterenol dose-response curves, a more precise measure than the attenuation of exercise-induced tachycardia previously used (4,9). Because we were working with experimental animals, we were able to study the effects of five stable and comparable sotalol dose levels in all animals. Our work therefore complements previous clinical studies (4, 9) and confirms the clear differences between sotalol doses needed for beta-blocking and class III actions. Clinical relevance. There is considerable variation in the magnitude of type III action reported for sotalol in patients. Several studies (13) (14) (15) (16) have reported increases of <IO% in corrected QT (QT,) intervals with mean sotalol doses ranging from 300 to 640 mg daily. Others (17) (18) (19) have reported mean QT, increases between 10% and 13.4% at mean sotalol plasma concentrations of 1.7 to 3 mgiliter. Thus, whereas changes in repolarization are produced by sotalol in humans at slightly lower concentrations than is the case in dogs, type III actions require clearly larger concentrations than those needed to cause beta-blockade. Type III effects are relatively minor at the commonly used dose range of 160 to 320 mg daily, which produces mean plasma sotalol concentrations in the range of 0.4 to 0.8 mgiliter (4).
The potential clinical role of sotalol's type III actions needs further appraisal. It is possible that selective action potential prolongation in diseased tissues, as shown previously for dogs with myocardial infarction (101, plays a role in sotalol's efficacy in the treatment of ventricular arrhythmias (15. 20, 21) . even at concentrations with modest class III actions on normal tissues. We found that sotalol produced significantly greater type III actions in the atrium compared with the ventricle. This result is in agreement with previous clinical observations (19, 22) and suggests that supraventricular arrhythmias may be controlled by lower sotalol concentrations than are necessary for ventricular arrhythmias.
to prevent lethal ventricular tachyarrhythmias, the drug is no more effective than other beta-blockers in preventing sudden death after myocardial infarction (23) ; however, the only long-term study of sotalol after infarction (24) used doses that would be inadequate to produce important changes in repolarization. Other trials (25) found no differences in the effects on ventricular refractoriness and tachyarrhythmias of sotalol and metoprolol, again at sotalol doses (160 to 320 mg/day) that our results indicate are insufficient to produce substantial class III effects. Consideration of the concentration-dependence of sotalol's type III action is important in analyzing the results of such clinical trials.
Conclusions. We have found that sotalol's pure class III actions require much larger concentrations than those producing beta-blockade. These pharmacodynamic differences must be considered in further studies of the mechanisms of sotalol's antiarrhythmic actions and their clinical importance.
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